NICE recommends capivasertib for advanced breast cancer Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.…
Chronic lymphocytic leukaemia: diagnosis and management An overview of how to diagnose, manage and monitor patients with chronic lymphocytic leukaemia, emphasising the important role of pharmacists.… Supported content
Engineering precision: developing the next generation of antibody drug conjugates Researchers are working to create a new generation of these targeted cancer therapies to improve efficacy and minimise off-target adverse effects.…
Testicular cancer: symptoms, diagnosis and management An overview of testicular cancer, its affected populations, diagnostic procedures and treatment options.…
NICE recommends olaparib for advanced breast cancer in final draft guidance The drug has previously been recommended for some types of ovarian cancer in England and for prostate cancer in Scotland.…
BRUKINSA is now reimbursed across the UK for R/R MZL Read more to learn how BRUKINSA could benefit your patients with R/R MZL.… Promotional content
Health inequalities included in updated cancer referral guidelines The Scottish government's ‘Cancer Strategy for Scotland 2023–2033’ highlights that there is “convincing evidence” that socioeconomic and health disparities are linked with increased diagnoses of more advanced cancers.…
Government advises chief pharmacists to coordinate aid between trusts amid radioisotope shortage According to a national patient safety alert issued on 25 October 2024, the radioisotope shortage stems from a combination of technical issues and essential maintenance work.…
NICE overturns decision on blood cancer treatment elranatamab Elranatamab is now recommended as a fourth-line treatment for relapsed and refractory multiple myeloma, according to updated guidance from the National Institute for Health and Care Excellence.…
NICE lifts restrictions on myeloma treatment teclistamab in final draft guidance The updated guidance recommends the monoclonal antibody for anyone with relapsed or refractory multiple myeloma who has received three or more lines of treatment and whose myeloma has progressed.…
